期刊文献+

替格瑞洛与氯吡格雷对急性STEMI患者急诊PCI术后炎症因子的影响 被引量:17

Effect on Inflammatory Factors between Ticagrelor and Clopidogrel after Emergency PCI about Patients with Acute ST-segment Elevation Myocardial Infarction
下载PDF
导出
摘要 为比较替格瑞洛与氯吡格雷对急性ST段抬高型心肌梗死(STEMI)患者急诊经皮冠状动脉介入术(PCI)术后炎症因子的影响,将176例急性STEMI且行急诊PCI术的患者分为替格瑞洛组(A组)58例、氯吡格雷常规组(B组)58例、氯吡格雷强化组(C组)60例,分别测定术前、术后12小时、术后7天、术后1个月、术后3个月、6个月时炎症因子C-反应蛋白(CRP)、白细胞介素-6(IL-6)、髓过氧物酶(MPO)、可溶性CD40受体(sCD40L)的含量,比较3组患者各炎症因子在不同时间点有无统计学差异。结果显示C组和A组较B组明显降低(P<0.05),有统计学意义,而A组较C组稍降低(P>0.05),但两者无统计学意义。由此可见,替格瑞洛的抗炎作用较常规剂量氯吡格雷作用明显增强,和强化剂量氯吡格雷作用相仿。 To compare the effect on inflammatory factors between ticagrelor and clopidogrel after emergency PCI about patients with acute ST-segment elevation myocardial infarction (STEMI), we divide 176 cases of acute STEMI patients who were undergone emergency PCI into ticagrelor group (group A) 58 cases, conventional clopidogrel group (group B) 58eases and strenghed clopidogrel group (group C) 60 patients. Inflammatory cytokines such as C-reactive protein (CRP), interleukin-6 (IL-6) ,myeloperoxidase (MPO) and soluble CD40 (sCD40L) were measured before surgery and 12 hours, 7 days, 1 month, 3months ,6months after surgery, compared the statistics of inflammatory factors at different time. The results showed the inflammatory factors levels of enhanced elopidogrel and ticagrelor group degrades more than conventional clopidogrel group (P〈0. 05), there was statistical significance, while the ticagrelor group degrades slightly lower than clopidogrel strenghed group (P 〉 0. 05), but there was no statistical significance. Thus the effect on inflammatory factors of tieagrelor is stronger than conventional clopidogrel, but near to strenghed elopidogrel.
作者 张阳阳 陈魁
出处 《医学与哲学(B)》 2014年第9期31-32,52,共3页 Medicine & Philosophy(B)
关键词 替格瑞洛 氯吡格雷 急性ST段抬高型心肌梗死 炎症因子 ticagrelor, clopidogrel, acute ST-segment elevation myocardial infarction, inflammatory factor
  • 相关文献

参考文献9

  • 1Wright R S,Anderson J L,Adams C D,et al. 2011 ACCF/AHA focused update of the guidelines for th agement of patients with unstable angina/non-ST elevation myocardial, infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in col- laboration with the American Academy of Family Physicians, Society for Gardiovascular Angiography and Interventions, and the Society of Tho- racic Surgeons[J]. J Am Col/Cardiol,2011 ,57(19) :e215-e367.
  • 2殷宇刚,王滨.瑞舒伐他汀对冠状动脉支架植入术后再狭窄以及血脂和炎症因子的影响[J].第二军医大学学报,2011,32(2):227-228. 被引量:39
  • 3Lim S Y,Jeong M H,Bae E H. predictive factors of major advers cardiac events in actue myocardial infarction patients complicated by cardlogenic shock undergoing primary percutaneous coronary inter- vention[J]. Circ J, 2005,69(2) : 154-158.
  • 4Armstrong E J, Morrow D A, Sabatine M S. Inflammatory biomark- ers in acute coronary syndromes, part I: introduction and cytokines [J]. Circulation,2006,113(6) :e72-e75.
  • 5Bisoendial R J,Kastelein J J,Peters S L,et al. Effects of CRP infu sion on endothelial function and coagulation in normocholesterolem- ie and hypercholesterolemie subjects[J]. J Lipid Res,2007,48(4): 952-960.
  • 6Antonino M J ,Mahla E,Bliden K P ,et al. Effect of long-term clopi dogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting[J]. Am J Cardiol, 2009,10.3 (11) :1546-1550.
  • 7Molero L,Lapez Farrg A,Mateos-Cdceres P J,et al. Effect of clo pidogrel on the expression of inflammatory markers in rabbit ische mic coronary artery[J].gr J Pharmacol,2005,146(3):419 -424.
  • 8Pels K, Schwimmbeck P L, Rosenthal P, et al. Long-term clopidogrel ad ministration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator pro- tein 1 activation in pigs[J]. Eur J Clin Invest,2009,39(3) :174-182.
  • 9Winning J, Reichel J, Eisenhut Y, et al. Anttplatelet drugs and outcome in severe infection., clinical impact and underlying mechanisms[J]. Plate- lets,2009,20(1) :50-51.

二级参考文献6

  • 1Regar E, Sianos G, Serruys P W. Stent development and local drug delivery[J]. Br Med Bull, 2001,59 : 227-248.
  • 2Rossouw J E. Lipid lowering interventions in angiographic trials [J]. Am J Cardiol,1995,76:86C -92C.
  • 3Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart J C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA I[J]. J Clin Invest, 2001,107 : 1423- 1432.
  • 4Davidson M,Ma P,Stein E A,Gotto A M Jr,Raza A,Chitra R, et al. Comparison of effects on low-density lipoprotein choles terol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type Ⅱ a or Ⅱ b hypercholesterolemia[J]. Am J Cardiol, 2002,89 : 268-275.
  • 5Ridker P M,Danielson E,Fonseca F A,Genest J,Gotto A M Jr, Kastelein J J, et al. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein[J]. N Engl J Med, 2008,359 : 2195-2207.
  • 6石先辉,贾如意.阿托伐他汀在急性冠状动脉综合征中的抗炎作用及临床应用[J].医学综述,2008,14(12):1888-1890. 被引量:25

共引文献38

同被引文献148

引证文献17

二级引证文献162

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部